Cipla Limited

14%

Revenue (YoY Growth in INR terms) EBITDA Margin R&D Spends2 Overall Cipla Overall Ex-covid 14% 12% Overall 21% Adj. margin1 ~22% 21% (YoY Growth) One-India (YoY Growth in INR terms) On

12%

enue (YoY Growth in INR terms) EBITDA Margin R&D Spends2 Overall Cipla Overall Ex-covid 14% 12% Overall 21% Adj. margin1 ~22% 21% (YoY Growth) One-India (YoY Growth in INR terms) One Ind

21%

wth in INR terms) EBITDA Margin R&D Spends2 Overall Cipla Overall Ex-covid 14% 12% Overall 21% Adj. margin1 ~22% 21% (YoY Growth) One-India (YoY Growth in INR terms) One India 27% Presc

22%

BITDA Margin R&D Spends2 Overall Cipla Overall Ex-covid 14% 12% Overall 21% Adj. margin1 ~22% 21% (YoY Growth) One-India (YoY Growth in INR terms) One India 27% Prescription business cro

27%

erall 21% Adj. margin1 ~22% 21% (YoY Growth) One-India (YoY Growth in INR terms) One India 27% Prescription business crossing $1Bn scale; continued traction in trade generics and consumer he

8%

traction in trade generics and consumer health North America NA revenue $594Mn (YoY Growth) 8% Continued momentum in respiratory franchise and peptide unlocking SAGA SAGA 6% (YoY Growth

6%

(YoY Growth) 8% Continued momentum in respiratory franchise and peptide unlocking SAGA SAGA 6% (YoY Growth in $ terms) SA Private 15% (YoY Growth in ZAR terms) Market beating growth in pr

15%

espiratory franchise and peptide unlocking SAGA SAGA 6% (YoY Growth in $ terms) SA Private 15% (YoY Growth in ZAR terms) Market beating growth in private business on steady launches Interna

5%

national Markets & API International Markets $385Mn Strong respiratory filings in Europe API 5% (YoY Growth in $ terms) Note:1. Excludes impact of one-time covid inventory and other charges of

INR 200 crore

(YoY Growth in $ terms) Note:1. Excludes impact of one-time covid inventory and other charges of ~INR 200 crores in Q4 | 2. Opex including depreciation Strong traction in One-India and US business drive Q4FY22

14.5%

stained traction across branded & generic markets EBITDA Margin Adj1 EBITDA Margin R&D spends2 14.5% 18%+ 16% (YoY Growth) One India SAGA 21% (Q4 YoY Growth in INR Terms) Sustained momentum

18%

traction across branded & generic markets EBITDA Margin Adj1 EBITDA Margin R&D spends2 14.5% 18%+ 16% (YoY Growth) One India SAGA 21% (Q4 YoY Growth in INR Terms) Sustained momentum acros

Registered Office

1

Registered Office

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com